PHIO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.59%

Insider Buying (Last 12 Months): $3,017.88

Insider Selling (Last 12 Months): $0.00

Phio Pharmaceuticals Insider Trading History Chart

Phio Pharmaceuticals Share Price & Price History

^$3.13

▼ -0.16 (-4.86%)

As of 10/30/2024 01:02 PM ET

Days: 30 | 90 | 365

Banking failure dead ahead

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Phio Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/6/2024	Robert J Bitterman	CEO	Buy	111	$6.75	$749.25	2,221
2/26/2024	Robert J Bitterman	CEO	Buy	277	$8.19	$2,268.63	2,110
6/30/2023	Robert J Bitterman	CEO	Buy	111	$25.92	$2,877.12	2,023
6/14/2023	Robert L Ferrara	Director	Buy	222	$27.90	$6,193.80	666
12/14/2022	Robert J Bitterman	Chairman	Buy	222	$3.51	$779.22	8,282
12/7/2022	Robert J Bitterman	Chairman	Buy	222	$3.51	$779.22	8,060
11/29/2022	Robert J Bitterman	Chairman	Buy	23	$3.60	$82.80	7,615
11/25/2022	Robert J Bitterman	Chairman	Buy	277	$3.78	$1,047.06	7,591
11/23/2022	Robert L Ferrara	Director	Buy	222	$3.69	$819.18	2,777
11/16/2022	Robert J Bitterman	Chairman	Buy	0	$15,750.00	$0.00

625,000% Gain

From Crypto Swap Profits | Ad

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

SEC Filings (Institutional Ownership Changes) for Phio Pharmaceuticals (NASDAQ:PHIO)

57.31% of Phio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Phio Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/14/2023	Anson Funds Management LP	22,571	$65K	0.0%	N/A	1.505%
8/10/2023	Cetera Investment Advisers	10,666	$31K	0.0%	N/A	0.711%
8/2/2023	Bank of Montreal Can	10,000	$38K	0.0%	N/A	0.667%
8/11/2022	Cetera Investment Advisers	75,000	$53K	0.0%	-16.7%	0.549%
11/16/2021	Cetera Investment Advisers	30,000	$61K	0.0%	N/A	0.222%
11/9/2021	BlackRock Inc.	35,592	$72K	0.0%	-17.8%	0.263%
9/17/2021	Virtu Financial LLC	27,110	$61K	0.0%	+74.7%	0.200%
8/13/2021	Vanguard Group Inc.	276,561	$0.63M	0.0%	+125.4%	2.043%
8/12/2021	Dimensional Fund Advisors LP	23,960	$54K	0.0%	-31.2%	0.177%
5/19/2021	Virtu Financial LLC	15,522	$42K	0.0%	N/A	0.115%
5/14/2021	Dimensional Fund Advisors LP	34,808	$93K	0.0%	+38.3%	0.257%
5/12/2021	Geode Capital Management LLC	87,501	$0.23M	0.0%	+330.6%	0.647%
5/10/2021	GSA Capital Partners LLP	132,333	$0.36M	0.1%	+30.5%	0.978%
3/26/2021	Susquehanna International Group LLP	12,058	$32K	0.0%	N/A	0.085%
3/8/2021	Dimensional Fund Advisors LP	25,177	$68K	0.0%	N/A	0.178%
2/25/2021	Dimensional Fund Advisors LP	25,177	$68K	0.0%	N/A	0.178%
2/4/2021	GSA Capital Partners LLP	101,401	$0.27M	0.0%	+376.6%	1.754%
12/11/2020	Virtu Financial LLC	35,929	$77K	0.0%	N/A	0.622%
11/6/2020	GSA Capital Partners LLP	21,278	$46K	0.0%	N/A	0.368%

Data available starting January 2016

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Today's Range

Now: $3.13

$3.06

$3.35

50 Day Range

MA: $3.05

$2.55

$3.70

52 Week Range

Now: $3.13

$2.40

$18.81

Volume

64,111 shs

Average Volume

43,820 shs

Market Capitalization

$1.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Who are the company insiders with the largest holdings of Phio Pharmaceuticals?: Phio Pharmaceuticals' top insider shareholders include:
Robert J Bitterman (Chairman)
Robert L Ferrara (Director)
Robert J Bitterman (CEO)
Learn More about top insider investors at Phio Pharmaceuticals.